Biomed Industries, a bio-pharmaceutical company, offered to acquire Quince Therapeutics, a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics, for $90m. "We believe our offer is very compelling as it provides Quince' shareholders with a highly certain and significant return and the ability to obtain liquidity for their shares, as well as the upside potential of Biomed," Lloyd L. Tran, Biomed Industries Chairman and CEO.